Zhang C, Ke J, Li J, Cai Q
Transl Cancer Res. 2024; 13(11):6057-6069.
PMID: 39697720
PMC: 11651734.
DOI: 10.21037/tcr-24-862.
Spirito F, Nocini R, Mori G, Albanese M, Georgakopoulou E, Sivaramakrishnan G
Int J Mol Sci. 2024; 25(23).
PMID: 39684701
PMC: 11641702.
DOI: 10.3390/ijms252312990.
Shahabinejad M, Bagheri Shirvan S, Fatemi G, Mohajer Tehran F
Dent Res J (Isfahan). 2024; 21:48.
PMID: 39376261
PMC: 11457987.
Du M, Lin Q, Yan S, Gao X, Yang C, Li Z
Ther Adv Med Oncol. 2024; 16:17588359241242962.
PMID: 38617023
PMC: 11010741.
DOI: 10.1177/17588359241242962.
Zheng B, He M, Han Y, Jiang X, Ou X, Zhang P
Curr Cancer Drug Targets. 2024; 24(9):952-966.
PMID: 38549541
DOI: 10.2174/0115680096281982240117114819.
Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma.
Santana V, Kruger V, Abrahao M, Cantu P, Brackmann R, Pandolfi G
Head Neck Pathol. 2024; 18(1):14.
PMID: 38457034
PMC: 10923758.
DOI: 10.1007/s12105-024-01618-5.
Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods.
Cheng Y, Song Z, Chen J, Tang Z, Wang B
Heliyon. 2024; 10(4):e25895.
PMID: 38380036
PMC: 10877294.
DOI: 10.1016/j.heliyon.2024.e25895.
Expression of PD-L1 and p-RPS6 in epithelial dysplasia and squamous cell carcinoma of the oral cavity.
Hanroongsri J, Amornphimoltham P, Younis R, Chaisuparat R
Front Oral Health. 2024; 5:1337582.
PMID: 38370876
PMC: 10869481.
DOI: 10.3389/froh.2024.1337582.
Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review.
Zdrenka M, Kowalewski A, Ahmadi N, Sadiqi R, Chmura L, Borowczak J
Biomol Biomed. 2023; 24(1):14-29.
PMID: 37877810
PMC: 10787614.
DOI: 10.17305/bb.2023.9265.
Molecular signaling in cancer stem cells of tongue squamous cell carcinoma: Therapeutic implications and challenges.
Joshi P, Waghmare S
World J Stem Cells. 2023; 15(5):438-452.
PMID: 37342225
PMC: 10277967.
DOI: 10.4252/wjsc.v15.i5.438.
Precancerous Lesions of the Head and Neck Region and Their Stromal Aberrations: Piecemeal Data.
Harris A, Andl T
Cancers (Basel). 2023; 15(8).
PMID: 37190121
PMC: 10137082.
DOI: 10.3390/cancers15082192.
Artificial intelligence in head and neck cancer diagnosis.
Bassani S, Santonicco N, Eccher A, Scarpa A, Vianini M, Brunelli M
J Pathol Inform. 2023; 13:100153.
PMID: 36605112
PMC: 9808017.
DOI: 10.1016/j.jpi.2022.100153.
Development and validation of novel nomograms to predict survival of patients with tongue squamous cell carcinoma.
Luo X, Zhang Y, Zhu R, Yang S, Zhou L, Zhu H
World J Clin Cases. 2022; 10(32):11726-11742.
PMID: 36405263
PMC: 9669853.
DOI: 10.12998/wjcc.v10.i32.11726.
Tumor invasion front in oral squamous cell carcinoma.
Cuevas-Gonzalez J, Cuevas-Gonzalez M, Espinosa-Cristobal L, Donohue Cornejo A
World J Clin Cases. 2022; 10(28):10387-10390.
PMID: 36246821
PMC: 9561579.
DOI: 10.12998/wjcc.v10.i28.10387.
Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma.
Kitichotkul K, Lertprasertsuke N, Kintarak S, Pongsiriwet S, Powcharoen W, Iamaroon A
Heliyon. 2022; 8(10):e10667.
PMID: 36212017
PMC: 9535272.
DOI: 10.1016/j.heliyon.2022.e10667.
Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.
Jiang S, Li X, Huang L, Xu Z, Lin J
Front Immunol. 2022; 13:988416.
PMID: 36119046
PMC: 9478105.
DOI: 10.3389/fimmu.2022.988416.
PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside.
Nocini R, Vianini M, Girolami I, Calabrese L, Scarpa A, Martini M
Clin Exp Dent Res. 2022; 8(3):690-698.
PMID: 35593124
PMC: 9209791.
DOI: 10.1002/cre2.590.
Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers.
Wang J, Ma X, Ma Z, Ma Y, Wang J, Cao B
Front Immunol. 2022; 13:810539.
PMID: 35493526
PMC: 9043345.
DOI: 10.3389/fimmu.2022.810539.
Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study.
Guerini Rocco E, Eccher A, Girolami I, Graziano P, Fontanini G, Vigliar E
Diagnostics (Basel). 2022; 12(2).
PMID: 35204568
PMC: 8871075.
DOI: 10.3390/diagnostics12020477.
Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy.
Rangel R, Pickering C, Sikora A, Spiotto M
Front Immunol. 2022; 13:840923.
PMID: 35154165
PMC: 8829003.
DOI: 10.3389/fimmu.2022.840923.